Richard Pestell, AO., MBBS, MD, PhD, MBA, FRACP, FACP, FRCP (Edin), FRCP (London) is a clinician scientist who currently serves as the President of the Pennsylvania Cancer and Regenerative Medicine Center, and Member Wistar Institute Cancer Center (Associate), in Philadelphia, USA.

He has been the principal investigator of >$86mMM USD in grants primarily from the NIH, published more than 700 works with >88,000 citations, H index 153). 

https://scholar.google.com/citations?view_op=search_authors&mauthors=richard+pestell&hl=en&oi=ao  He has authored 1 book, 52 book chapters and delivered 285 invited lectures.

He holds multiple issued patents in cancer diagnostics and treatment.

He led cancer not–for-profits, directed two USA Cancer Centers (Lombardi Comprehensive Cancer Center, and the Sidney Kimmel Cancer Center at Thomas Jefferson University) founded Departments, Institutes and several biotechnology companies. He is past President of INCTR (USA), a global not-for-profit working to impact cancer in the developing world and was founding Director of the Delaware Valley Institute for Clinical and Translational Science (University of Delaware, Thomas Jefferson University, Nemours and Christiana). He was most recently Executive Vice President Thomas Jefferson University, Philadelphia, USA.

He was the Winthrop Fellow at Harvard Medical School and was Clinical Fellow at Massachusetts General Hospital. Dr. Pestell completed his M.B., BS at the University of Western Australia, and conducted clinical training in Internal Medicine, Oncology and Endocrinology. He received M.D. and Ph.D. degrees from Melbourne University, and his MBA from NYU, Stern School of Business.

Dr. Pestell identified key genetic targets for cancer, including cyclins and CCR5. His preclinical studies of cyclin D1 in breast cancer were cited as the basis for the clinical trials of CDK inhibitors, now approved by the FDA for treatment of cancer. His preclinical studies of CCR5 inhibitors are cited as the basis for the current clinical trials of CCR5 inhibitors for cancer.   

He has received awards for his research, clinical care and impact on improving health care access including RD Wright Medallion, The Eric Susman Prize in Medicine, Doctor of Medical Sciences, Honoris Causa, University of Melbourne, Doctor Honoris Causa, University of Western Australia and appointment as an Officer of the Order of Australia in the 2019 Queen's Birthday Honors for “distinguished service to medicine, and to medical education, as a researcher and physician in the fields of endocrinology and oncology”.  https://en.wikipedia.org/wiki/Richard_Pestell

He previously and or currently served as a member of the Editorial Board of 14 journals and as a Reviewers of >18 funding agencies in >9 countries.

Principal investigator of federal NIH grants (~ 240 NIH grants https://grantome.com/search?q=@author%20%20Richard%20Pestell), including 3 sequential Program multi-investigator grants (2002-2016 (multi-institution (100-150 investigators) (P30 CA 056036), NIH RO1 and R21 grants. In addition I received multi-state grants (IRG-08-060-02 ), State grants (SAP#4100047652), and both PI and multi investigator grants from the Dept. of Defense, receiving >$85M USD to date